Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort

Disease-specific COVID-19 pediatric comorbidity has not been studied effectively to date. Atopy and food anaphylaxis disease states require improved characterization of SARS-CoV-2 infection risk. To provide the first such characterization, we assessed serum samples of a highly atopic, food anaphylac...

Full description

Bibliographic Details
Main Authors: Nathan L. Marsteller, Diana J. Fregoso, Tricia L. Morphew, Inderpal S. Randhawa
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Antibodies
Subjects:
Online Access:https://www.mdpi.com/2073-4468/10/2/22
_version_ 1797531691190845440
author Nathan L. Marsteller
Diana J. Fregoso
Tricia L. Morphew
Inderpal S. Randhawa
author_facet Nathan L. Marsteller
Diana J. Fregoso
Tricia L. Morphew
Inderpal S. Randhawa
author_sort Nathan L. Marsteller
collection DOAJ
description Disease-specific COVID-19 pediatric comorbidity has not been studied effectively to date. Atopy and food anaphylaxis disease states require improved characterization of SARS-CoV-2 infection risk. To provide the first such characterization, we assessed serum samples of a highly atopic, food anaphylactic, asymptomatic pediatric cohort from across the US during the height of the pandemic. From our biobank, 172 pediatric patient serum samples were characterized specific to atopic, food anaphylactic, and immunologic markers in the US at the beginning of the pandemic, from 1 February to 20 April 2020. Clinical and demographic data were further analyzed in addition to sample analysis for SARS-CoV-2 IgM and IgG ELISA. SARS-CoV-2 antibody results were positive in six patients (4%). Nearly half of the pediatric patients had a history of asthma (49%). Total IgE, total IgG, and IgG1-3 were similar in those positive and negative to SARS-CoV-2. Median total IgG4 in the SARS-CoV-2 positive group was nearly three times (<i>p</i>-value = 0.02) that of the negative group. Atopy controller medications did not confer additional benefit. Our data suggest that food anaphylaxis and highly atopic children are not at increased risk for SARS-CoV-2 seropositivity. This specific population appears either at equal or potentially less risk than the general population. Total and specific IgG4 may be a novel predictor of SARS-CoV-2 infection risk specific to the allergic pediatric population.
first_indexed 2024-03-10T10:47:21Z
format Article
id doaj.art-f4dcb55d4cb84dc08af5618a261e486c
institution Directory Open Access Journal
issn 2073-4468
language English
last_indexed 2024-03-10T10:47:21Z
publishDate 2021-06-01
publisher MDPI AG
record_format Article
series Antibodies
spelling doaj.art-f4dcb55d4cb84dc08af5618a261e486c2023-11-21T22:31:17ZengMDPI AGAntibodies2073-44682021-06-011022210.3390/antib10020022Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic CohortNathan L. Marsteller0Diana J. Fregoso1Tricia L. Morphew2Inderpal S. Randhawa3The Translational Pulmonary and Immunology Research Center (TPIRC), Long Beach, CA 90806, USAThe Translational Pulmonary and Immunology Research Center (TPIRC), Long Beach, CA 90806, USAMorphew Consulting, LLC, Bothell, WA 98021, USAThe Translational Pulmonary and Immunology Research Center (TPIRC), Long Beach, CA 90806, USADisease-specific COVID-19 pediatric comorbidity has not been studied effectively to date. Atopy and food anaphylaxis disease states require improved characterization of SARS-CoV-2 infection risk. To provide the first such characterization, we assessed serum samples of a highly atopic, food anaphylactic, asymptomatic pediatric cohort from across the US during the height of the pandemic. From our biobank, 172 pediatric patient serum samples were characterized specific to atopic, food anaphylactic, and immunologic markers in the US at the beginning of the pandemic, from 1 February to 20 April 2020. Clinical and demographic data were further analyzed in addition to sample analysis for SARS-CoV-2 IgM and IgG ELISA. SARS-CoV-2 antibody results were positive in six patients (4%). Nearly half of the pediatric patients had a history of asthma (49%). Total IgE, total IgG, and IgG1-3 were similar in those positive and negative to SARS-CoV-2. Median total IgG4 in the SARS-CoV-2 positive group was nearly three times (<i>p</i>-value = 0.02) that of the negative group. Atopy controller medications did not confer additional benefit. Our data suggest that food anaphylaxis and highly atopic children are not at increased risk for SARS-CoV-2 seropositivity. This specific population appears either at equal or potentially less risk than the general population. Total and specific IgG4 may be a novel predictor of SARS-CoV-2 infection risk specific to the allergic pediatric population.https://www.mdpi.com/2073-4468/10/2/22antibodyatopyinfectious disease
spellingShingle Nathan L. Marsteller
Diana J. Fregoso
Tricia L. Morphew
Inderpal S. Randhawa
Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort
Antibodies
antibody
atopy
infectious disease
title Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort
title_full Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort
title_fullStr Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort
title_full_unstemmed Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort
title_short Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort
title_sort immune response to sars cov 2 in an asymptomatic pediatric allergic cohort
topic antibody
atopy
infectious disease
url https://www.mdpi.com/2073-4468/10/2/22
work_keys_str_mv AT nathanlmarsteller immuneresponsetosarscov2inanasymptomaticpediatricallergiccohort
AT dianajfregoso immuneresponsetosarscov2inanasymptomaticpediatricallergiccohort
AT tricialmorphew immuneresponsetosarscov2inanasymptomaticpediatricallergiccohort
AT inderpalsrandhawa immuneresponsetosarscov2inanasymptomaticpediatricallergiccohort